Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

155.01
-1.1300-0.72%
Post-market: 155.010.00000.00%19:54 EDT
Volume:1.83M
Turnover:283.74M
Market Cap:295.76B
PE:23.43
High:156.38
Open:156.11
Low:154.44
Close:156.14
52wk High:170.46
52wk Low:112.34
Shares:1.91B
Float Shares:1.86B
Volume Ratio:0.86
T/O Rate:0.10%
Dividend:4.67
Dividend Rate:3.01%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:7.12
PE(LYR):21.68

Loading ...

Novartis price target raised to CHF 142 from CHF 132 at Citi

TIPRANKS
·
Jul 23

Novartis (NVS) Receives a Sell from Goldman Sachs

TIPRANKS
·
Jul 22

Novartis AG Stock (NVS) Moved Up by 3.42% on Jul 21: Key Drivers Unveiled

TradingKey
·
Jul 22

Movement Alert|Novartis Rises 3.76% in Regular Trading, Q2 Earnings Significantly Beat Expectations Signaling Growth Recovery

Market Focus
·
Jul 21

Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline

Benzinga
·
Jul 21

Potential Middle East Ceasefire Lifts US Equity Futures Pre-Bell

MT Newswires Live
·
Jul 21

Novartis Returns to Growth After Key Drugs Offset Patent Expirations

Dow Jones
·
Jul 21

Key Drug Sales Drive Novartis Back to Revenue Growth

Deep News
·
Jul 21

Stocks to Watch: GM, Novartis, Swatch, Micron

Dow Jones
·
Jul 21

Movement Alert|Novartis Rises 3.58% in Pre-Market Trading, Q2 Earnings Significantly Beat Expectations Signaling Growth Recovery

Market Focus
·
Jul 21

Novartis Guidance Points to Slow Second Half

Dow Jones
·
Jul 21

Novartis Q2 Core Earnings Down, Sales Rise

MT Newswires Live
·
Jul 21

Novartis Benefits from Timing Effects That Will Drag Next Results

Dow Jones
·
Jul 21

Movement Alert|Novartis Overnight Rise 3.47%, Q2 Earnings Significantly Beat Expectations Signaling Return to Growth

Market Focus
·
Jul 21

Novartis Beats Expectations, but Guidance Reiteration Surprises

Dow Jones
·
Jul 21

Novartis Q2 Results Exceed Expectations as Strong Sales of Innovative Drugs Offset Generic Competition, Signaling Return to Growth

Stock News
·
Jul 21

Novartis Q2 Adj. EPS $2.41 Beats $2.13 Estimate, Sales $14.408B Beat $14.042B Estimate

Benzinga
·
Jul 21

Novartis Recovery Prospects, Drug Pipeline in Focus

Dow Jones
·
Jul 20

European Pharma Stocks' Underperformance Shouldn't Last

Dow Jones
·
Jul 17

Novartis' Fabhalta Receives FDA Traditional Approval for Primary IgA Nephropathy

MT Newswires Live
·
Jul 17